Protein kinase C as a target for the treatment of respiratory syncytial virus
OwnerShyam S. Mohapatra, Homero Gabriel San Juan Vergarainventors
Life of this patent
Estimating the term…
Abstract
The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a PKC inhibitor, to a patient in need thereof. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC,inhibitor and a pharmaceutically acceptable carrier.
Claims20
A method of inhibiting a respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient.
A pharmaceutical composition comprising at least one protein kinase C (PKC) inhibitor and a pharmaceutically acceptable carrier.
A host cell that has been genetically modified with a nucleotide sequence encoding at least one PKC inhibitor, wherein said nucleotide sequence is expressed in said cell.
Dependencies are inferred from the claim text.